Skip to main content
. 2023 May 9;77(6):875–882. doi: 10.1093/cid/ciad267

Figure 2.

Figure 2.

Median tenofovir alafenamide fumarate (TAF) plasma concentration (upper) and mean tenofovir (TFV) plasma concentration (lower) versus time curves of children on TAF combined with dolutegravir (DTG), atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or lopinavir/ritonavir (LPV/r). Twenty-two of 104 (21%) children did not have a sample at 0.5 h after dose: 6 on DTG, 6 on ATV/r, 5 on DRV/r, and 5 on LPV/r.